Main Article Content
Neuroleptic malignant syndrome (NMS) is a severe motor syndrome occurring as a consequence of neuroleptic treatment. We present a case of a 67-year-old Caucasian woman with a history of a major depressive disorder with psychotic features. During her third hospital admission, symptoms of autonomic instability, hyperpyrexia, severe extrapyramidal side effects, and delirium appeared, suggesting NMS due to concomitant treatment with risperidone and quetiapine, among other drugs. Despite several consecutive pharmacological treatments (lorazepam, bromocriptine and amantadine) and prompt initiation of electroconvulsive therapy (ECT), clinical improvement was observed only after combining bupropion with ECT. The symptoms that had motivated the admission gradually remitted and the patient was discharged home. Bupropion increases dopaminergic activity in both the nucleus accumbens and the prefrontal cortex. Therefore, from a physiopathological standpoint, bupropion has a potential role in treating NMS. However, there is scarce evidence supporting this approach and therefore future cases should be carefully considered.
Downloads month by month
Download data is not yet available.
How to Cite
Foguet-Boreu, Q., Coll-Negre, M., Serra-Millàs, M., & Cavalleria-Verdaguer, M. (2018). Neuroleptic malignant syndrome: a case responding to electroconvulsive therapy plus bupropion. Clinics and Practice, 8(1). https://doi.org/10.4081/cp.2018.1044
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.